p53 partial loss-of-function mutations sensitize to chemotherapy.

Oncogene · 2022 · PMC8837531 · PMID 34907344

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Similar as observed by immunohistochemistry of spleen samples, 2 h after treatment upregulation of the signatures was already highly significant in p53 +/+ leukemias, but still variable in E177R leukemias.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.